138 related articles for article (PubMed ID: 6378798)
1. Augmentation of protective and antibacterial activity induced by muramyl dipeptides in CBA/N defective mice with X-linked immunodeficiency for Salmonella enteritidis infection.
Onozuka K; Saito-Taki T; Nakano M
Infect Immun; 1984 Aug; 45(2):424-7. PubMed ID: 6378798
[TBL] [Abstract][Full Text] [Related]
2. Effect of muramyl dipeptide analog on Salmonella enteritidis infection in beige mice with Chediak-Higashi syndrome.
Onozuka K; Saito-Taki T; Nakano M
Microbiol Immunol; 1984; 28(11):1211-21. PubMed ID: 6097802
[TBL] [Abstract][Full Text] [Related]
3. Anti-infectious activity of liposomal muramyl dipeptides in immunodeficient CBA/N mice.
Phillips NC; Chedid L
Infect Immun; 1987 Jun; 55(6):1426-30. PubMed ID: 3553001
[TBL] [Abstract][Full Text] [Related]
4. The adjuvant effect of a muramyl dipeptide (MDP) analog on temperature-sensitive Salmonella mutant vaccine.
Onozuka K; Shinomiya H; Cho N; Saito-Taki T; Nakano M
Int J Immunopharmacol; 1989; 11(7):781-7. PubMed ID: 2689364
[TBL] [Abstract][Full Text] [Related]
5. Effect of muramyl dipeptide and its stearoyl derivatives on resistance to Sendai virus infection in mice.
Ishihara C; Hamada N; Yamamoto K; Iida J; Azuma I; Yamamura Y
Vaccine; 1985 Dec; 3(5):370-4. PubMed ID: 2417426
[TBL] [Abstract][Full Text] [Related]
6. Effect of MDP-Lys(L18) as a mucosal immunoadjuvant on protection of mucosal infections by Sendai virus and rotavirus.
Fukushima A; Yoo YC; Yoshimatsu K; Matsuzawa K; Tamura M; Tono-oka S; Taniguchi K; Urasawa S; Arikawa J; Azuma I
Vaccine; 1996 Apr; 14(6):485-91. PubMed ID: 8782344
[TBL] [Abstract][Full Text] [Related]
7. Augmentation of immune responses by a muramyl dipeptide analog, MDP-Lys(L18).
Akasaki M; Takashi T; Kita Y; Tsukada W
Agents Actions; 1987 Oct; 22(1-2):144-50. PubMed ID: 3318323
[TBL] [Abstract][Full Text] [Related]
8. Stimulation of nonspecific resistance to infection induced by muramyl dipeptide analogs substituted in the gamma-carboxyl group and evaluation of N alpha-muramyl dipeptide-N epsilon-stearoyllysine.
Matsumoto K; Otani T; Une T; Osada Y; Ogawa H; Azuma I
Infect Immun; 1983 Mar; 39(3):1029-40. PubMed ID: 6341226
[TBL] [Abstract][Full Text] [Related]
9. Protective effect of MDP-Lys(L18), a synthetic derivative of muramyldipeptide, on murine cytomegalovirus infection.
Eizuru Y; Nakagawa N; Hamasuna R; Minamishima Y
Nat Immun; 1992; 11(4):225-36. PubMed ID: 1384831
[TBL] [Abstract][Full Text] [Related]
10. Acute and chronic polyarthritis induced by an aqueous form of 6-O-acyl and N-acyl derivatives of N-acetylmuramyl-L-alanyl-D-isoglutamine in euthymic rats and athymic nude rats.
Kohashi O; Kohashi Y; Shigematsu N; Ozawa A; Kotani S
Lab Invest; 1986 Sep; 55(3):337-46. PubMed ID: 3489128
[TBL] [Abstract][Full Text] [Related]
11. Effect of MDP-Lys(L18), a derivative of MDP, on enhancing host resistance against Hantaan virus infection in newborn mice.
Yoo YC; Yoshimatsu K; Hatsuse R; Tamura M; Yoshida R; Tono-oka S; Arikawa J; Azuma I
Vaccine; 1995 Oct; 13(14):1300-5. PubMed ID: 8585284
[TBL] [Abstract][Full Text] [Related]
12. MDP-Lys(L18), a lipophilic derivative of muramyl dipeptide, inhibits the metastasis of haematogenous and non-haematogenous tumours in mice.
Yoo YC; Saiki I; Sato K; Azuma I
Vaccine; 1994 Feb; 12(2):175-60. PubMed ID: 8147100
[TBL] [Abstract][Full Text] [Related]
13. Adjuvant activity of muramyl dipeptide derivatives to enhance immunogenicity of a hantavirus-inactivated vaccine.
Yoo YC; Yoshimatsu K; Koike Y; Hatsuse R; Yamanishi K; Tanishita O; Arikawa J; Azuma I
Vaccine; 1998; 16(2-3):216-24. PubMed ID: 9607033
[TBL] [Abstract][Full Text] [Related]
14. Effect of L18-MDP(Ala), a synthetic derivative of muramyl dipeptide, on nonspecific resistance of mice to microbial infections.
Osada Y; Mitsuyama M; Une T; Matsumoto K; Otani T; Satoh M; Ogawa H; Nomoto K
Infect Immun; 1982 Jul; 37(1):292-300. PubMed ID: 6809630
[TBL] [Abstract][Full Text] [Related]
15. Stimulation of non-specific resistance to infection by muroctasin.
Otani T; Une T; Osada Y
Arzneimittelforschung; 1988 Jul; 38(7A):969-76. PubMed ID: 3056426
[TBL] [Abstract][Full Text] [Related]
16. Augmentation by priming with interferon-gamma of the binding of a muramyl dipeptide derivative to macrophages resulting in synergistic macrophage activation.
Nagao S; Sato K; Osada Y
Jpn J Cancer Res; 1987 Jan; 78(1):80-6. PubMed ID: 3102442
[TBL] [Abstract][Full Text] [Related]
17. Effect of stearoyl-N-acetylmuramyl-L-alanyl-D-isoglutamine on host resistance to Corynebacterium kutscheri infection in cortisone-treated mice.
Ishihara C; Yamamoto K; Hamada N; Azuma I
Vaccine; 1984 Dec; 2(4):261-4. PubMed ID: 6531965
[TBL] [Abstract][Full Text] [Related]
18. Antigenicity study of muroctasin.
Yamaguchi F; Hattori H; Wagai N; Tsukada W
Arzneimittelforschung; 1988 Jul; 38(7A):1034-7. PubMed ID: 3190797
[TBL] [Abstract][Full Text] [Related]
19. In vitro and in vivo effects of MDP-Lys(L18) on mouse megakaryocyte progenitor cells (CFU-Meg).
Komiya I; Kuriya S; Akahane K; Nomura T
Exp Hematol; 1992 May; 20(4):517-22. PubMed ID: 1568468
[TBL] [Abstract][Full Text] [Related]
20. Mutagenicity studies of muroctasin.
Shimada H; Hattori C; Sato T
Arzneimittelforschung; 1988 Jul; 38(7A):1031-3. PubMed ID: 3056424
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
